We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Holographic Imaging-Based COVID-19 Test Could Detect Both SARS-CoV-2 Infection and Antibodies in 30 Minutes

By LabMedica International staff writers
Posted on 14 Oct 2020
A new method using holographic imaging to detect both viruses and antibodies has the potential to aid in medical diagnoses and, specifically, those related to the COVID-19 pandemic. More...


The team of New York University (New York, NY, USA) scientists who have developed the new method base their test on holographic video microscopy, which uses laser beams to record holograms of their test beads. If fully realized, the proposed test could be done in under 30 minutes, is highly accurate, and can be performed by minimally trained personnel. Moreover, the method can test for either the virus (current infection) or antibodies (immunity).

The surfaces of the beads are activated with biochemical binding sites that attract either antibodies or virus particles, depending on the intended test. Binding antibodies or viruses causes the beads to grow by a few billionths of a meter, which the NYU researchers have shown they can detect through changes in the beads’ holograms.

“Our approach is based on physical principles that have not previously been used for diagnostic testing,” said David Grier, a professor of physics at NYU and one of the researchers on the project. “We can detect antibodies and viruses by literally watching them stick to specially prepared test beads.”

“We can analyze a dozen beads per second,” explained Grier, “which means that we can cut the time for a reliable thousand-bead diagnostic test to 20 minutes. And we can measure those changes rapidly, reliably, and inexpensively.”

The holographic video microscopy is performed by an instrument named xSight.
“This instrument can count virus particles dispersed in patients’ saliva and also detect and differentiate antibodies dissolved in their blood,” added Grier. “This flexibility is achieved by changing the composition of the test beads to model what we are testing.

“Each type of bead tests for the presence of a particular target, but can also test for several targets simultaneously. Our holographic analysis distinguishes the different test beads by their size and by their refractive index—an easily controlled optical property.”

The scientists say that this capability can be used to develop libraries of test beads that may be combined into test kits for mixing with patient samples. This will support doctors in distinguishing among possible diagnoses, speeding patients’ treatment, reducing the risk of misdiagnosis, and cutting the cost of healthcare.

Related Links:
New York University


Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Pipette
Accumax Smart Series
Gold Member
Ketosis and DKA Test
D-3-Hydroxybutyrate (Ranbut) Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.